CoChat

Therapeutic mTOR Inhibition in Autosomal Dominant Polycystic Kidney Disease: What Is the Appropriate Serum Level?

Open access
Canaud, G., Knebelmann, B., Harris, P.C, Vrtovsnik, F., Correas, J.‐M., Pallet, N., Heyer, C.M, Letavernier, E., Bienaimé, F., Thervet, E., Martinez, F., Terzi, F., Legendre, C. · 2010 · American Journal of Transplantation
Cited by 69

The DOI matches its Crossref record.

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited renal disease, and sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been shown to significantly retard cyst expansion in animal models. The optimal therapeutic dose of sirolimus is not yet defined. Here, we report the history of a previously unknown ADPKD deceased donor whose kidneys were engrafted in two different recipients. One of the two received an immunosuppressive regimen based on sirolimus for 5 years while the other did not. After transplantation, both patients developed severe transplant cystic disease. Donor DNA sequence identified a new hypomorphic mutation in PKD1. The rate of cyst growth was identical in the two patients regardless of the treatment. While sirolimus treatment reduced the activation of mTOR in peripheral blood mononuclear cells, it failed to prevent mTOR activation in kidney tubular cells, this could account for the inefficiency of treatment on cyst growth. Together, our results suggest that the dose of sirolimus required to inhibit mTOR varies according to the tissue.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1600-6143.2010.03152.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 69

Metadata

Authors
Canaud, G., Knebelmann, B., Harris, P. C., Vrtovsnik, F., Correas, J. ‐., Pallet, N., Heyer, C. M., Letavernier, E., Bienaimé, F., Thervet, E., Martinez, F., Terzi, F., & Legendre, C.
Venue
American Journal of Transplantation
Publisher
Elsevier BV
Published
2010-07
Volume
10
Issue
7
Pages
1710-1715
ISSN
1600-6135 (ISSN-L)
OpenAlex
W1550480781
Cited by
69
References
0
FWCI
3.19
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Therapeutic mTOR Inhibition in Autosomal Dominant Polycystic Kidney Disease: What Is the Appropriate Serum Level? https://app.cochat.ai/papers/10.1111/j.1600-6143.2010.03152.x
The paper
Canaud, G., Knebelmann, B., Harris, P. C., Vrtovsnik, F., Correas, J. ‐., Pallet, N., Heyer, C. M., Letavernier, E., Bienaimé, F., Thervet, E., Martinez, F., Terzi, F., & Legendre, C. (2010). Therapeutic mTOR Inhibition in Autosomal Dominant Polycystic Kidney Disease: What Is the Appropriate Serum Level? American Journal of Transplantation. https://doi.org/10.1111/j.1600-6143.2010.03152.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.